Skip to content

EV / EBITDA at other companies

AdaptHealth logo
AdaptHealthAHCO
8.5×+2.7×
Evolent Health, Inc. logo
Evolent Health, Inc.EVH
24.5×-26.3×
The Pennant Group, Inc. logo
The Pennant Group, Inc.PNTG
22.9×-1.7×
ResMed logo
ResMedRMD
15.2×-3.1×
UFP Technologies logo
UFP TechnologiesUFPT
14×-2.6×
Merit Medical Systems logo
Merit Medical SystemsMMSI
14.2×-10.5×

Other financials

Income statement

See full
Revenue$75.4M+27.5%
Gross profit$42.8M+28.7%
Operating income$4.3M+11.8%
Net income$2.6M-1.6%
EPS (diluted)$0.060.0%

Balance sheet

See full
Cash & equivalents$9.8M-3.9%
Total debt$12.4M+84.0%
Total equity$143.9M+6.8%
Total assets$197.4M+10.8%

Cash flow

See full
Operating cash flow$8.1M+183%
CapEx$6.7M-56.6%
Free cash flow$1.4M+111%

Valuation

See full
Market cap$448.16M+71.3%
Enterprise value$450.83M+74.6%
P/E30.1×+8.8×
P/S1.6×+0.4×

Profitability

See full
Gross margin57.6%-1.1pp
Operating margin8.2%-0.2pp
Net margin5.2%-0.1pp
FCF margin9%

Returns & leverage

See full
Return on equity10.7%+0.9pp
Debt / equity0.1×0.0×
Current ratio1.2×-0.2×

Where this comes from

Calculated from Viemed Healthcare, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Viemed Healthcare, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Viemed Healthcare, Inc.'s ev / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Viemed Healthcare, Inc.'s EV / EBITDA?
Viemed Healthcare, Inc. (VMD) reported EV / EBITDA of 6.8× in Q1 2026.
How has Viemed Healthcare, Inc.'s EV / EBITDA changed year-over-year?
Viemed Healthcare, Inc.'s EV / EBITDA increased by 7.5% year-over-year, from 6.3× to 6.8×.
What is the long-term trend for Viemed Healthcare, Inc.'s EV / EBITDA?
Over 5 years (2020 to 2025), Viemed Healthcare, Inc.'s EV / EBITDA has grown at a -6.4% compound annual growth rate (CAGR), from 7.7× to 5.5×.
What does EV / EBITDA mean?
Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.